Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Passage Bio Inc (NQ: PASG )

1.150 -0.050 (-4.17%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 19, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 284,080
Open 1.200
Bid (Size) 1.100 (1)
Ask (Size) 1.260 (2)
Prev. Close 1.200
Today's Range 1.120 - 1.200
52wk Range 0.5751 - 1.790
Shares Outstanding 55,598,796
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
PASG Stock Earnings: Passage Bio Beats EPS for Q4 2023
PASG stock results show that Passage Bio beat analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
Passage Bio Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Recent Business Highlights
From Passage Bio
Via GlobeNewswire

Performance

YTD
+27.62%
+27.62%
1 Month
-17.86%
-17.86%
3 Month
+23.02%
+23.02%
6 Month
+69.37%
+69.37%
1 Year
+11.65%
+11.65%

More News

Read More
Passage Bio to Participate in Upcoming Investor Conferences
From Passage Bio
Via GlobeNewswire
7 Analyst-Backed Stocks With Promising 10-Bagger Potential
Via InvestorPlace
Recap: Passage Bio Q3 Earnings
Via Benzinga
Passage Bio to Present at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
From Passage Bio
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
7 Nano-Cap Stocks That Pack a Serious Punch for Their Weight
Via InvestorPlace
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Why BlackBerry Shares Are Trading Lower By Over 5%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Neurology-Focused Passage Bio Reveals Initial Data From Dementia Study, Outlines Strategic Priorities
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Passage Bio Announces Promising Initial Data From Phase 1/2 Clinical Trial of PBFT02 in FTD-GRN and Updated Strategic Priorities
From Passage Bio
Via GlobeNewswire
Passage Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
From Passage Bio
Via GlobeNewswire
Monday.Com To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Tuesday
Via Benzinga
Passage Bio Reports Third Quarter 2023 Financial Results and Provides Recent Business Highlights
From Passage Bio
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Passage Bio to Present at Guggenheim’s 5th Annual Inflammation, Neurology & Immunology Conference
From Passage Bio
Via GlobeNewswire
Passage Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Passage Bio
Via GlobeNewswire
Passage Bio to Present at Chardan’s 7th Annual Genetic Medicines Conference
From Passage Bio
Via GlobeNewswire
Passage Bio Reports Second Quarter 2023 Financial Results and Provides Recent Business Highlights
From Passage Bio
Via GlobeNewswire
Passage Bio Announces Promising Interim Clinical Data from First Eight Patients with GM1 Gangliosidosis in Imagine-1 Study
From Passage Bio
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.